Unraveling the GUT-salivary gland axis: microbial and microbial metabolite-based strategies for sjögren's syndrome therapy
Active Grant Awarded Last action
- Award ID
- R01DE035499
- Recipient
-
ADA Forsyth Institute, Inc. UEI MZ9DFVC2J1B7
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $629,029
Award facts
- Assistance listing
- 93.121 Oral Diseases and Disorders Research
- Completion date 4% complete
- Place of performance
- Cambridge, MA 02142, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Dental and Craniofacial Research awarded $629,029 to ADA Forsyth Institute, Inc. (doing business as The Forsyth Institute) on September 3, 2026, under Assistance Listing 93.121, Oral Diseases and Disorders Research, through Grant R01DE035499.
The award funds research titled "Unraveling the Gut-Salivary Gland Axis: Microbial and Microbial Metabolite-Based Strategies for Sjogren's Syndrome Therapy." The project tests whether healthy gut microbiota, healthy fecal microbiota transplant, and specific beneficial gut bacteria protect or improve salivary gland integrity and function in Sjogren's disease by producing short-chain fatty acids and other metabolites. Its two mechanistic aims are to identify microbial metabolites that link the gut and salivary glands and to define cellular targets and molecular changes in salivary tissue.
Place of performance is Cambridge, Massachusetts (ZIP 02142). The period of performance ends May 31, 2031. Dollars obligated equal the full $629,029. The source does not identify sub-recipients for this award.
Description
- Abstract
- Salivary gland function is chronically impaired in sjӧgren's disease (SJD), which is a chronic autoimmune exocrine gland disorder with no cure or effective treatment available. Dysregulated innate and adaptive immune responses, including heightened interferon responses, drive the onset and chronic persistence of salivary gland inflammation, damage and functional impairment. There is a pressing need for novel, effective therapies that protect/improve salivary gland function and mitigate SJD. GUT microbiome dysbiosis is closely linked to various autoimmune and inflammatory diseases, including sjӧgren's disease, while healthy fecal microbiota transplant (FMT) shows promise in mitigating inflammatory pathology and preserving/restoring tissue function. In murine models of SJD, transplanting certain GUT bacterial species or their metabolites, such as short-chain fatty acids (SCFAS) alleviates salivary gland pathology. However, many critical knowledge gaps remain, particularly regarding the tissue protective mechanisms of the GUT-salivary gland axis. The main objective of this project is to define the GUT-salivary gland axis in SJD, focusing on the salivary gland-beneficial effects of healthy FMT and specific GUT bacteria, and unraveling two mechanistic layers underlying these actions: (I) microbial metabolites as key mediators linking the GUT and salivary glands, and (II) cellular targets and molecular changes in salivary tissues. We will test the central hypothesis that healthy GUT microbiota harbor bacterial species that protect/improve salivary gland integrity and function, and transplantation of these healthy GUT microbiota or beneficial bacterial species can exert protective and therapeutic effects in SJD-associated salivary gland pathology by producing SCFAS and other metabolites, which mediate GUT-salivary gland communication and mitigate interferon-induced detrimental responses in salivary epithelial cells. In aim 1 of the project, we will elucidate key salivary tissue mechanisms underlying the protective effects of healthy FMT in a murine model of SJD observed in our preliminary studies. We will also evaluate the therapeutic potential of healthy FMT on established SJD in this mouse model. In aim 2, we will examine the protective and therapeutic effects of two specific GUT bacterial species, identified in our preliminary studies, on salivary gland function in the murine model of SJD. In aim 3, we will investigate the previously unexplored effects of SCFAS on human salivary gland cells and peripheral and immune cells from SJD patients, and identify key beneficial microbial metabolites linking GUT microbiome to salivary glands in FMT and SJD in both mice and humans. This project will employ advanced immunological, microbiological and systems biological approaches, including 16S rrna gene sequencing for microbiome profiling, transcriptomic analysis of salivary gland epithelial populations, and metabolomic profiling. The novel and highly translatable findings from this project will significantly advance the development of innovative microbial-based therapies for SJD and other inflammatory salivary gland disorders.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $629,029 |
Quick answers
Who received award R01DE035499?
R01DE035499 was awarded to ADA Forsyth Institute, Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 3, 2026.
How much is award R01DE035499 worth?
$629,029 has been obligated on R01DE035499.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award